Glenmark Pharmaceuticals has informed that it enclosed a press release today titled ‘Glenmark Pharmaceuticals receives ANDA approval for Sodium Phenylbutyrate Tablets USP, 500 mg’.
The above information is a part of company’s filings submitted to BSE.